Millie
your market intelligence analyst
Search Results
236 results
Your search is now limited to «Eli Lilly» expert search.
NASDAQ 10/18/2019 10:57
Meanwhile, the FDA granted approval to Lilly’s LLY Reyvow (lasmiditan) oral tablets for migraine as well as J&J/Bayer’s BAYRY oral anticoagulant, Xarelto and Roche’s flu treatment Xofluza for expanded patient populations.
More from NASDAQ:
PMLiVE 10/17/2019 05:31
Lilly’s presence in cancer is led by lung cancer chemotherapy drug Alimta (pemetrexed), which brought in $2.1bn in sales last year down from a peak of around $2.8bn in 2014 as a result of patent expirations.
More from PMLiVE:
BioPharma Dive 10/16/2019 11:21
Lilly offered few details beyond disclosing the drug, called pegilodeckin, did not meet the study's primary endpoint of improving overall survival versus a trio of chemotherapies.
More from BioPharma Dive:
ENDPOINTS 10/16/2019 07:54
Over the past few years, the deluge of capital into biotech has helped lead to a dramatic shift in focus on new drug approvals, as startups are now able to raise enough cash to get through a pivotal and onto the market.
More from ENDPOINTS:
Channel NewsAsia (Singapore) 10/16/2019 07:45
World Eli Lilly and Co said on Wednesday its experimental pancreatic cancer treatment in combination with a cocktail of chemotherapies did not meet the main goal in a late-stage study.
More from Channel NewsAsia (Singapore):
ETHealthWorld (India) 10/16/2019 07:32
Eli Lilly and Co said on Wednesday its experimental pancreatic cancer treatment in combination with a cocktail of chemotherapies did not meet the main goal in a late-stage study.
More from ETHealthWorld (India):
FierceMedicalDevices 10/16/2019 07:15
With a sense of morose inevitability, Lilly didn’t go against the flow of this dismal tide.
More from FierceMedicalDevices:
Reuters.com 10/16/2019 07:10
REUTERS/Vincent Kessler (Reuters) - Eli Lilly and Co said on Wednesday its experimental pancreatic cancer treatment in combination with a cocktail of chemotherapies did not meet the main goal in a late-stage study.
More from Reuters.com:
PR Newswire 10/16/2019 06:45
About Lilly Oncology For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them.
More from PR Newswire:
(MENAFN - Market Research Explore) The Global Insulin API Market research report focuses on exploring the developments and growth strategies of the global Insulin API industry. The...
More from Middle East North Africa Financial Network (MENAFN):
Korean Biomedical Review 10/14/2019 05:13
The Korean branch of Eli Lilly said it has presented the phase 4 IXORA-R study, which compared Taltz against Tremfya in people living with moderate to severe plaque psoriasis.
More from Korean Biomedical Review:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications